An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age

Diabetes Research Center, Brussels Free University, VUB, Laarbeeklaan 103, 1090 Brussels, Belgium.
Diabetologia (Impact Factor: 6.67). 11/2011; 55(2):413-20. DOI: 10.1007/s00125-011-2376-1
Source: PubMed

ABSTRACT The appearance of autoantibodies (Abs) before diabetes onset has mainly been studied in young children. However, most patients develop type 1 diabetes after the age of 15 years. In first-degree relatives aged under 40 years, we investigated the frequency of seroconversion to (persistent) Ab positivity, progression to diabetes and baseline characteristics of seroconverters according to age.
Abs against insulin (IAA), glutamate decarboxylase (GADA), insulinoma-associated protein 2 (IA-2A) and zinc transporter 8 (ZnT8A) were measured during follow-up of 7,170 first-degree relatives.
We identified 379 (5.3%) relatives with positivity for IAA, GADA, IA-2A and/or ZnT8A (Ab(+)) at first sampling and 224 (3.1%) at a later time point. Most seroconversions occurred after the age of 10 years (63%). During follow-up, Abs persisted more often in relatives initially Ab(+) (76%) than in seroconverters (53%; p < 0.001). In both groups diabetes developed at a similar pace and almost exclusively with Ab persistence (136 of 139 prediabetic individuals). For both groups, progression was more rapid if Abs appeared before the age of 10 years. Baseline characteristics at seroconversion did not vary significantly according to age.
Seroconversion to (persistent) Ab(+) occurs regardless of age. Although the progression rate to diabetes is higher under age 10 years, later seroconverters (up to age 40 years) have similar characteristics when compared with age-matched initially Ab(+) relatives and generate an important minority of prediabetic relatives, warranting their identification and, eventually, enrolment in prevention trials.

Download full-text


Available from: Katrijn Verhaeghen, Sep 28, 2015
37 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Autoantibodies to islet cell proteins currently provide the only reliable indication that the process leading to type 1 diabetes has started. The period from the first detection of islet autoantibodies to clinical onset of diabetes can last months or years. Longitudinal birth cohort family studies give crucial information concerning the natural history of islet autoimmunity and have already shown that islet autoantibodies, which precede diabetes development, often appear in early infancy. In this issue of Diabetologia, Ziegler et al (DOI: 10.1007/s00125-012-2472-x ) and Parikka et al (DOI: 10.1007/s00125-012-2523-3 ) report findings from their birth cohort studies after numerous children have entered adolescence, allowing a more complete picture of islet autoimmunity in childhood to be revealed. Both groups are in accord that, between 6 months and 3 years of age, there is an explosion of islet autoimmunity in susceptible children and that the great majority (approximately 80%) of genetically at-risk children who present with diabetes before adolescence develop islet autoimmunity at this young age. These findings emphasise the importance of early life events in disease pathogenesis and have major implications for efforts aimed at preventing type 1 diabetes.
    Diabetologia 05/2012; 55(7):1873-6. DOI:10.1007/s00125-012-2583-4 · 6.67 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The SNP rs13266634 encodes either an Arginine (R) or a Tryptophan (W) (R325W) at the amino acid position 325 in the Zinc Transporter 8 (ZnT8) protein. Autoantibodies (Ab) that recognize ZnT8R, ZnT8W or both at the polymorphic site are common in newly diagnosed type 1 diabetes (T1D) patients. The epitope specificity and affinity of ZnT8Ab are poorly understood, but may be of importance for the prediction and clinical classification of T1D. Therefore, the aims were to 1) determine the immunogenicity of short (318-331) ZnT8 peptides in mice, and 2) test the affinity of short and long (268-369) ZnT8 proteins in T1D patients positive for either ZnT8WAb or ZnT8RAb. Sera from BALB/cByJ mice immunized with short R, W or Q (Glutamine) ZnT8 peptides were tested for ZnT8-peptide antibodies in ELISA and radiobinding assay (RBA). Using reciprocal permutation experiment, short synthetic ZnT8R and ZnT8W (318-331) and long in vitro transcription translation ZnT8R and ZnT8W (268-369) proteins, were tested in competitive RBA with R- and W- monospecific T1D sera samples. All mouse sera developed non-epitope specific peptide-antibodies in ELISA and only 6/12 mice had ZnT8-RWQ antibodies in RBA. Both long ZnT8R and ZnT8W (268-369) but not any short, proteins displaced labeled ZnT8 (268-369) proteins in binding to T1D ZnT8Ab-specific sera. The reciprocal cross-over tests showed that half maximal displacement varied 2-11-fold indicating variable affinity of patient ZnT8Ab, signifying crucial autoantibody epitope spreading. The present approach should make it possible to dissect the importance of the R325W ZnT8 autoantigen epitope in the T1D pathogenesis.
    Scandinavian Journal of Immunology 11/2012; 77(1). DOI:10.1111/sji.12008 · 1.74 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We investigated whether HLA-A*24 typing complements screening for HLA-DQ and for antibodies (Abs) against insulin, GAD, IA-2 (IA-2A), and zinc transporter-8 (ZnT8A) for prediction of rapid progression to type 1 diabetes (T1D). Persistently Ab(+) siblings/offspring (n = 288; aged 0-39 years) of T1D patients were genotyped for HLA-DQA1-DQB1 and HLA-A*24 and monitored for development of diabetes within 5 years of first Ab(+). HLA-A*24 (P = 0.009), HLA-DQ2/DQ8 (P = 0.001), and positivity for IA-2A ± ZnT8A (P < 0.001) were associated with development of T1D in multivariate analysis. The 5-year risk increased with the number of the above three markers present (n = 0: 6%; n = 1: 18%; n = 2: 46%; n = 3: 100%). Positivity for one or more markers identified a subgroup of 171 (59%) containing 88% of rapid progressors. The combined presence of HLA-A*24 and IA-2A(+) ± ZnT8A(+) defined a subgroup of 18 (6%) with an 82% diabetes risk. Among IA-2A(+) ± ZnT8A(+) relatives, identification of HLA-A*24 carriers in addition to HLA-DQ2/DQ8 carriers increased screening sensitivity for relatives at high Ab- and HLA-inferred risk (64% progression; P = 0.002). In conclusion, HLA-A*24 independently predicts rapid progression to T1D in Ab(+) relatives and complements IA-2A, ZnT8A, and HLA-DQ2/DQ8 for identifying participants in immunointervention trials.
    Diabetes 11/2012; 62(4). DOI:10.2337/db12-0747 · 8.10 Impact Factor
Show more